Rajiv Advani

🫀 GLP-1: From Glucose Control to Cardiovascular Protection GLP-1 receptor agonists (GLP-1RAs) have officially moved beyond diabetes therapy — they are now cardiovascular drugs. This comprehensive 2026 review in J Clin Invest synthesizes preclinical and clinical evidence showing that GLP-1 signaling exerts direct vascular and cardiac protection, far beyond glucose lowering. 🔬 In experimental models, GLP-1RAs: Reduce atherosclerotic plaque size Stabilize plaques (↑ fibrous cap thickness, ↓ inflammation) Suppress foam cell formation Reduce systemic inflammatory signaling Improve post-MI cardiac function Protect against ischemia/reperfusion injury Improve HFpEF phenotypes (↓ fibrosis, ↓ hypertrophy, ↑ diastolic function) Importantly, many of these benefits appear independent of glucose, cholesterol, or weight loss. 📊 In clinical trials (CVOTs): ~14–15% relative reduction in 3-point MACE Significant reductions in CV death, MI, stroke 14% reduction in heart failure hospitalization SELECT trial: 20% MACE reduction in obese patients without diabetes The emerging message is clear: GLP-1RAs are not just metabolic drugs — they are anti-atherogenic, anti-inflammatory, and cardioprotective agents. 💡 Mechanistically, benefits likely stem from: Plaque stabilization Systemic inflammation reduction Improved myocardial metabolism Favorable body fat redistribution Modest BP and lipid effects ⚠️ Uncertainties remain in HFrEF, but data in HFpEF and ASCVD are compelling. We are witnessing a paradigm shift: Treating cardiometabolic disease by targeting shared inflammatory and metabolic pathways. GLP-1 is no longer just about HbA1c. It’s about vascular biology.